|
Authors
|
Ziemba, B. ; Sikorska, H. ; Jander, M. ; Kuncman, W. ; Danilewicz, M. ; Appelhans, D. ; Bryszewska, M. ; Borowiec, M. ; Franiak-Pietryga, I.
|
|
Title
|
Anti-tumour activity of glycodendrimer nanoparticles in a subcutaneous MEC-1 xenograft model of human chronic lymphocytic leukemia
|
|
Date
|
01.01.2020
|
|
Number
|
56067
|
|
Abstract
|
BACKGROUND:Chronic Lymphocytic Leukaemia (CLL) is an indolent disorder, which mainly affects older adults. Since the advent of chemoimmunotherapy, great progress has been made in its treatment. However, some patients develop a more aggressive form of the disease and are included in the group of high-risk CLL patients with a dismal prognosis and a need for new therapies. OBJECTIVE:Maltotriose-modified poly(propylene imine) dendrimers were presented as potential agents in targeted therapy for CLL in the murine xenograft model. METHODS:Tumour, brain and internal organs resected from NOD scid gamma mice were subjected to gross and histopathological evaluation. RESULTS:Results of ex vivo tissues examination indicated that open shell glycodendrimers prevented/inhibited the spread of CLL to the brain and internal organs and its transformation into a more aggressive form. CONCLUSION:The results of the study have a potentially important impact on the design of future personalized therapies as well as clinical trials.
|
|
Publisher
|
Anti-Cancer Agents in Medicinal Chemistry
|
|
Wikidata
|
|
|
Citation
|
Anti-Cancer Agents in Medicinal Chemistry 20 (2020) 325-334
|
|
DOI
|
https://doi.org/10.2174/1871520619666191019093558
|
|
Tags
|
|
